Mr. Tucker is an accomplished and seasoned leader with more than 30 years of healthcare management, consulting, and medical device experience, with a proven track record of developing and executing market strategies.
Prior to joining RFPi, Mr. Tucker co-founded HealthCare Markets Group (HMG), a strategic advisory and investment-banking firm, which has completed over $2.0 billion in transactions. Mr. Tucker has worked closely with some of the industry’s leading healthcare companies on improving performance, enhancing shareholder value, establishing distribution networks, and formulating and implementing restructuring initiatives.
Mr. Tucker has directed turnarounds, initiated acquisitions, and divestitures, formed alliances and joint ventures, raised capital in the form of equity and debt, counseled companies relative to initial public offerings and private placements. Mr. Tucker has served in senior leadership roles including Chief Executive Officer, Chief Restructuring Officer and Chief Development Officer for a diverse range of healthcare organizations.
Mr. Tucker has served a large and diverse clientele which has included public companies such as, HCA Healthcare, Tenet Healthcare, HealthSouth (Encompass Health Corp.), Community Health System, Hologic, Inc. (as senior level executive), Insight Health Services, Triumph Healthcare (Kindred Healthcare), US Oncology, Providence Service Corporation ( as a founding partner) and numerous private and non-profit healthcare systems such as WellStar Health System, Crozer-Keystone Health System and Houston Methodist Hospital System.
Prior to HMG, Mr. Tucker held senior and regional positions in Philips Medical Systems, US Surgical Corp., American Scientific Products and Coulter Electronics.
Serial startup entrepreneur Jeff Basham has years of experience advancing health-care innovations from concept to fruitful acquisition or commercialization. He was founding CEO of a group of companies that became Closure Medical, which developed the first successful synthetic wound closure glue and eventually was sold to Johnson & Johnson for $500 million.
Mr. Basham also directed the turnaround of Entegrion, a hemostatic-focused startup for which he raised new capital by organizing and closing on more than $50 million worth of U.S. Department of Defense development funds.
Most recently, Mr. Basham was vice president of business development at Metrics Inc., a contract pharmaceutical development and manufacturing organization. Led by Mr. Basham’s business development efforts, the company experienced double-digit revenue growth annually.
Peter Geiger spent seven years serving as chief financial officer at DSM Pharmaceuticals, a contract pharmaceutical manufacturing producing $2 billion worth of consumer products annually.
Mr. Geiger brings to RFPi significant financial leadership in health services startups. As managing general partner of Geiger Investments Ltd., Mr. Geiger applies his expertise in company valuation to help generate above-market returns for partners.
Holding an undergraduate degree in behavioral neuroscience from Lehigh University, Mr. Geiger graduated with honors from the Wharton School of Business at the University of Pennsylvania with an MBA in finance and strategic management.
Chief Medical Officer and Co-Founder
Internationally renowned cardiovascular surgeon Dr. Bruce Ferguson is one of the creators of RFPi’s proprietary and innovative Multi-spectral Physiologic Visualization (MSPV) real-time imaging technology platform. He continues to be instrumental in guiding the development of clinical applications and physician adoption of the MSPV platform as Chief Medical Officer of RFPi, Inc.
Dr. Ferguson is a highly regarded leader in his field of expertise. He was a pioneer in Near-Infrared Fluorescence (NIRF) imaging in cardiac surgery, having performed over 1000 cases using that imaging modality as standard of care. He has served for 11 years as the international surgical lead on the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) Trial, the purpose of which is to determine the best management strategy for higher-risk patients with stable ischemic heart disease, a study sponsored by the National Heart, Blood and Lung Institute (NHLBI). He also served as Principal Investigator on ECU’s component of a joint Duke University/East Carolina Heart Institute clinical site of the NHLBI Cardiac Surgical Network from 2007-2013.
An early adopter of data-driven and quality-outcomes medicine who has extensive experience in clinical databases, Dr. Ferguson was the first chairman of the Society of Thoracic Surgeons (STS) Council on Quality, Research and Patient Safety, which manages the organization’s national databases. He was a member of the Institute of Medicine group that authored “Best Care at Lower Cost: The Path to Continuously Learning Health Care in America.” He led for 7 years the largest quality improvement RCT in medicine using the STS Adult Cardiac database, funded by AHRQ.
Dr. Ferguson has been extramurally funded by Health and Human Services entities continuously since 1989, at Washington University in St. Louis, Duke University, Louisiana State University in New Orleans, and the ECU Brody School of Medicine. He is the Principal Investigator on RFPi’s three STTR and SBIR grant projects to date. He led RFPi’s experimental and clinical research efforts required for FDA 510(k) Class II approval of the first form factor, iCertainty™.
He is a member of the National Academy of Inventors, with currently 14 allowed patents, nine of which involve different aspects of the MSPV technology solutions.
Dr. Ferguson is leading RFPi’s First in Person iCertainty™ (FIRST) Study, a multi-center clinical use study of iCertainty™ across multiple surgical specialties and applications. This study is establishing the RFPi-ARMUS Cloud Repository and Surgeon Web Portal as the clinical knowledge engine behind the MSPV technology.
Chief Science and Technical Officer and Founder
Highly regarded optical physicist Dr. Cheng Chen began creating RFPi’s medical-imaging technology in 2008. With expertise in imaging algorithm, visualization and research & development, Dr. Chen proved critical for the IP strategy and patent application of this technology, and his vision will lead to further application, new design, and intellectual property product expansions. His patent portfolio currently has six patents, with over thirty additional applications under review nationally and internationally.
Dr. Chen earned his doctorate in Bio-Medical Physics from East Carolina University which led to his career in optical imaging of turbid biological medium and publishing numerous papers in peer reviewed scientific journals. Previously serving in the Physics and Engineering Departments, Dr. Chen has retired as associate professor at East Carolina University and is now an adjunct associate professor with the university. He is a member of National Academy of Inventors.
With expertise in visible and near infrared imaging, Dr. Chen was one of the first to recognize the enormous clinical potential for real-time analysis of blood flow and perfusion. Utilizing fluorescence, laser speckle imaging and multi-spectral imaging, Dr. Chen developed the software for the Complex Angiography and Perfusion Analysis (CAPA) platform and is one of the inventors of the Multi-Spectral Physiologic Visualization imaging technology.